A personal perspective of patient-centred clinical trials

Trevor Tyne; Elizabeth Ivimey; Leanne Duggan; Jia Liu

doi:10.18632/oncotarget.28776

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Rapamycin Press LLC dba Impact Journals is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

A personal perspective of patient-centred clinical trials

Trevor Tyne, Elizabeth Ivimey, Leanne Duggan and Jia Liu _

PDF | Full Text | How to cite

Oncotarget. 2025; 16:808-812. https://doi.org/10.18632/oncotarget.28776

Metrics: PDF 65 views | Full Text 194 views | ?

Abstract

Trevor Tyne1^,*, Elizabeth Ivimey1^,*, Leanne Duggan1^,* and Jia Liu1^,2^,3

1 The Kinghorn Cancer Centre, St Vincent’s Hospital, Sydney, NSW, Australia

2 School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia

3 Garvan Institute of Medical Research, Sydney, NSW, Australia

* These authors contributed equally to this work

Correspondence to:

Jia Liu,

email:

[email protected]

Keywords: precision oncology; patient-centric care; clinical trials; tumor agnostic; drug development

Received: October 13, 2025 Accepted: October 21, 2025 Published: November 14, 2025

Copyright: © 2025 Tyne et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Key objective: To illustrate the first-hand journey of three early phase trial participants highlighting their benefits and challenges of participation and patient-centric innovations required to improve trial experience.

Knowledge generated: Early phase trials have traditionally centred on dose-finding and toxicity. However as they have increased in number and improved in therapeutic intent, the patient experience becomes increasingly important. This article illustrates benefits of participation including access to novel therapies, support and close monitoring but challenges around eligibility criteria, finances, and communication. Proposed solutions including trial navigators, enhanced communication training, and greater flexibility in enrolment criteria to improve trials access.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28776

Publication Alerts

Oncoscience

Post-Publication Promotion

Research Perspectives:

A personal perspective of patient-centred clinical trials

Abstract